FDA approves Circassia's Duaklir Pressair for maintenance therapy for patients with chronic obstructive pulmonary disease
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
chronic obstructive pulmonary disease (COPD) is a progressive disease that is mainly associated with smoking, air pollution or occupational contact, which causes breathing difficulties and an increase in the number of episodes of breathing difficultiesrecently, Circassia(http:// announcedthat the U.SFDA(http://has approved Duaklir Pressair (aclidinium bromide and formoterol fumarate), ammonium aptin/Fumotrogan powder inhaler, for the maintenance of patients with chronic obstructive pulmonary diseaseDuaklir Pressair is a fixed-dose combination of long-acting venomic antagonists (LAMA) ammonium adi bromide (400mcg) and long-acting beta2 receptor agonists (LABA) fumaricfothero (12mcg)product(http://, delivered twice a day through preloaded, breath-driven Pressair multi-dose inhalersThe product has been approved in many countries and regions around the world, including the European Union, and is listed and sold under multiple brand namesDuaklir is given the drug through the Pressair inhalerPressair inhalers have proven to be the patient's first choice compared to other(http://of inhalersdevices commonly used in COPD Pressair is a multi-dose dry powder inhaler (DPI) that combines two positive feedback mechanisms and pre-fills Duaklir to relax the airway muscles, helpkeeping the airways open and making it easier for patients to breathe
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
